

IND SAFETY REPORT: INITIAL WRITTEN REPORT

TO: Division of Drug Oncology Products, Center for Drug Evaluation and Research, FDA

FAX: 301-796-9845

1. IND NUMBER
74019

2. AGENT NAME
Sunitinib malate (SU011248 L-malate; Sutent®)

3. DATE
March 24, 2010

4. SPONSOR
Division of Cancer Treatment and Diagnosis, National Cancer Institute

5. REPORTER'S NAME, TITLE, AND INSTITUTION
Pamela Harris, MD –Senior Investigator for Investigational Therapeutics 1, Investigational Drug Branch, CTEP, DCTD, NCI

6. PHONE NUMBER
301-496-1196

7. FAX NUMBER
301-402-0428

8. PROTOCOL NUMBER (AE #)
ADVL0612 (AE# 1733378)

9. PATIENT IDENTIFICATION
799609

10. AGE
18

11. SEX
Male

12. DESCRIPTION OF ADVERSE EVENT

The patient is an 18-year-old male with peritoneal mesothelioma who experienced grade 3 dilated intestinal loops and pneumatosis while on a phase 1 trial using the investigational agent sunitinib malate. He began his first course of treatment on March 2, 2010, and received the last dose of sunitinib malate on March 17, 2010 (Cycle 1, Day 16). On March 18, 2010 (Cycle 1, Day 17), the patient presented to the clinic with a complaint of severe constant periumbilical/upper abdominal pain. He also complained of nausea, vomiting and diarrhea which had started 2 days earlier. His abdominal X-ray showed dilated small and large bowel loops with some air-fluid levels. This was followed by an abdominal CT scan, which revealed diffuse intramural gas distributed in the small and large bowel walls with associated bowel wall thickening. There was no evidence of free air. It was felt that this may have been caused by the investigational agent based on the stability of the underlying malignant disease. The investigational agent was held and the patient was admitted to the hospital. He was started on a morphine drip and antibiotics. At this time, the patient remains hospitalized. Additional information has been requested from the investigational site. There is a reasonable possibility that the experience may have been caused by the drug.

13. DOSE, ROUTE, AND SCHEDULE

**Cycle = 42 Days
Sunitinib malate: 15 mg/m² PO daily as powder on Days 1-28**

14. DATES OF TREATMENT

The patient started the investigational therapy on March 2, 2010 and received the last dose of sunitinib malate on March 17, 2010 (Cycle 1, Day 16).

15. ACCRUAL AND IND EXPERIENCE

**Number of patients enrolled in NCI-sponsored clinical trials using sunitinib = 2332
There have been no other cases of dilated intestinal loops and pneumotosis reported to the NCI through AdEERS as serious adverse events for sunitinib malate.**

16. COMMENTS

AT THIS TIME, NO OTHER INFORMATION IS AVAILABLE. IF UPON FURTHER INVESTIGATION RELEVANT INFORMATION BECOMES AVAILABLE, THEN A FOLLOW-UP REPORT WILL BE SUBMITTED IN ACCORDANCE WITH 21CFR 312.32(d)(2).

DISCLAIMER per 21 CFR 312.32(e): THIS SAFETY REPORT DOES NOT NECESSARILY REFLECT A CONCLUSION OR ADMISSION BY THE CTEP IDB SENIOR INVESTIGATOR/SPONSOR THAT THE INVESTIGATIONAL AGENT/THERAPY CAUSED OR CONTRIBUTED TO THE ADVERSE EXPERIENCE BEING REPORTED.

0002